Business Context and Reporting Period
This Form 8-K Current Report was filed by Alphatec Holdings, Inc. on May 29, 2020. The filing details significant changes to the Company's capital structure, specifically the amendment of an existing credit facility and the termination of a prior credit agreement.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance metrics such as revenue or cash flow, which are not provided in this document.
- Debt Expansion: The Company expanded its secured term loan with Squadron Medical Finance Solutions LLC by $35,000,000.
- Interest Rate: The loan bears interest at one-month LIBOR + 8% per annum, subject to a 10% floor and a 13% ceiling.
- Maturity Date: The term was extended by two years, with the new maturity date set for May 31, 2025.
- Repayment Schedule: Interest-only payments are due monthly through November 2022. Principal payments of $29 million will be made in equal monthly installments beginning December 2022, followed by a $71 million lump-sum payment at maturity.
- Equity Issuance: The Company issued warrants to purchase an aggregate of 537,910 shares of common stock at an exercise price of $4.88 per share to Squadron and Tawani Holdings LLC.
Material Changes Versus Prior Period
The Company executed a material restructuring of its debt obligations on May 29, 2020:
- Termination of Prior Debt: The Borrowers repaid in full all outstanding principal, accrued interest, and fees under the "MidCap Credit Agreement" (originally dated August 30, 2013).
- Termination of Commitment: The Company formally terminated a Commitment Letter dated February 28, 2020, with Perceptive Credit Holdings III, LP.
- Warrant Adjustments: The expiration date of previously issued warrants to Squadron and Tawani was amended to May 29, 2027, aligning with the new warrants issued in this transaction.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing does not contain forward-looking guidance regarding revenue or earnings. The primary strategic action was securing additional liquidity and extending the debt maturity profile.
Risks and Contingencies:
- Dilution Risk: The issuance of 537,910 warrants at $4.88 per share introduces potential dilution. These warrants include price-based, weighted average anti-dilution adjustments if the Company issues equity at prices below $4.88, subject to Nasdaq listing rules.
- Interest Rate Risk: The loan interest rate is variable (LIBOR + 8%) with a floor of 10%, exposing the Company to significant interest expense if rates rise or remain at the floor.
- Liquidity Requirements: The repayment structure requires a substantial lump-sum payment of $71 million at maturity in 2025, creating a significant future cash outflow obligation.
Important Facts for Investor Verification
- Verify the total outstanding principal balance of the new Term Loan after the $35 million expansion.
- Confirm the Company's current cash position and liquidity sources to service the interest-only payments and the eventual $71 million balloon payment in 2025.
- Review the impact of the 537,910 new warrants on the Company's fully diluted share count and potential future dilution triggers.
- Assess the Company's ability to meet the 10% interest rate floor given current market conditions and the Company's operating cash flow.